Autologous dendritic cell-tumor fusion vaccine (Teikyo University)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous dendritic cell-tumor fusion vaccine (Teikyo University)

Drug Alias Name自体树突细胞融合疫苗（帝京大学）

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsGastrointestinal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTeikyo Post University Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTeikyo Post University Inc

Active IndicationsN/A

Inactive IndicationsGastrointestinal Neoplasms

Other Information

ATC CodeN/A